Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
First Claim
Patent Images
1. A method for evaluating the therapeutic efficacy of an aromatic-cationic peptide on a disease or condition characterized by mitochondrial dysfunction in a subject, comprising:
- assaying the level of a population of activated monocytes present in a biological sample obtained from the subject; and
comparing the level of the population of activated monocytes observed in step (a) with the level of a corresponding population of activated monocytes observed in a biological sample obtained from the subject following administration of a dose of an aromatic-cationic peptide,wherein the aromatic-cationic peptide is identified as having a therapeutic effect on the disease or condition characterized by mitochondrial dysfunction if the level of the population of activated monocytes in the biological sample following the administration of the aromatic-cationic peptide is reduced compared to the level of the population of activated monocytes observed in step (a).
4 Assignments
0 Petitions
Accused Products
Abstract
The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.
-
Citations
20 Claims
-
1. A method for evaluating the therapeutic efficacy of an aromatic-cationic peptide on a disease or condition characterized by mitochondrial dysfunction in a subject, comprising:
-
assaying the level of a population of activated monocytes present in a biological sample obtained from the subject; and comparing the level of the population of activated monocytes observed in step (a) with the level of a corresponding population of activated monocytes observed in a biological sample obtained from the subject following administration of a dose of an aromatic-cationic peptide, wherein the aromatic-cationic peptide is identified as having a therapeutic effect on the disease or condition characterized by mitochondrial dysfunction if the level of the population of activated monocytes in the biological sample following the administration of the aromatic-cationic peptide is reduced compared to the level of the population of activated monocytes observed in step (a). - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A method for evaluating the therapeutic efficacy of an aromatic-cationic peptide on a disease or condition characterized by mitochondrial dysfunction in a subject, comprising:
-
a. assaying the ratio of different monocyte types present in a biological sample obtained from the subject; and b. comparing the ratio of different monocyte types observed in step (a) with the ratio of corresponding monocyte types observed in a biological sample obtained from the subject following administration of a dose of an aromatic-cationic peptide, wherein the aromatic-cationic peptide is identified as having a therapeutic effect on the disease or condition characterized by mitochondrial dysfunction if the ratio of different monocyte types in the biological sample following the administration of the aromatic-cationic peptide is altered compared to the ratio of different monocyte types observed in step (a). - View Dependent Claims (9, 10, 11, 12, 13)
-
-
14. A method for evaluating the therapeutic efficacy of an aromatic-cationic peptide on a disease or condition characterized by mitochondrial dysfunction in a subject, comprising:
-
a. assaying at least one biomarker of mitochondrial physiology of a population of monocytes present in a biological sample obtained from the subject; and b. comparing the biomarker of mitochondrial physiology of the population of monocytes observed in step (a) with the biomarker of mitochondrial physiology of a corresponding population of monocytes observed in a biological sample obtained from the subject following administration of a dose of an aromatic-cationic peptide, wherein the aromatic-cationic peptide is identified as having a therapeutic effect on the disease or condition characterized by mitochondrial dysfunction if the biomarker of mitochondrial physiology of the population of monocytes in the biological sample following the administration of the aromatic-cationic peptide is similar to the biomarker of mitochondrial physiology of a corresponding population of monocytes in a reference sample obtained from a healthy subject. - View Dependent Claims (15, 16, 17, 18, 19, 20)
-
Specification